Unknown

Dataset Information

Administration of the K<sub>Ca</sub> channel activator SKA-31 improves endothelial function in the aorta of atherosclerosis-prone mice.


ABSTRACT:

Introduction

Atherosclerosis remains a major risk factor for vascular dysfunction and cardiovascular (CV) disease. Pharmacological enhancement of endothelial Ca2+-activated K+ channel activity (i.e., KCa2.3 and KCa3.1) opposes vascular dysfunction associated with ageing and type 2 diabetes (T2D) in ex vivo and in vivo preparations. In the current study, we have investigated the efficacy of this strategy to mitigate endothelial dysfunction in the setting of atherogenesis.

Methods

Male apolipoprotein E knockout (Apoe-/-) mice fed a high fat diet (HFD) were treated daily with the KCa channel activator SKA-31 (10 mg/kg), the KCa3.1 channel blocker senicapoc (40 mg/kg), or drug vehicle for

SUBMITTER: Vera OD 

PROVIDER: S-EPMC11906683 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature